Maze Therapeutics (MAZE) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 8, 2026, with voting available online or virtually.

• Shareholders are encouraged to review proxy materials and vote by June 7, 2026.

Voting matters and shareholder proposals

• Election of two Class I director nominees: Jason Coloma, Ph.D., and Neil Kumar, Ph.D.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Board recommends voting "For All" director nominees and "For" auditor ratification.

• Other business may be addressed as appropriate during the meeting.

Board of directors and corporate governance

• Board slate includes two Class I director nominees up for election at the annual meeting.